COMP <GO>
KOD vs ABBV // REVENUE GROWTH (YOY)
Kodiak Sciences Inc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: KOD 3
— ABBV 11
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $99.18 (-1.22%) • MKT CAP: $6.31B
revenue-growth
1.10%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KOD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KOD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.16% | 3.47% | -5.63 | ABBV | /fcf-yield <GO> |
| Operating Margin | -13.30% | 24.60% | -37.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -13.00% | 6.90% | -19.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 1.10% | 8.60% | -7.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.70 | 5.33 | +11.37 | KOD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | KOD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.5 | 72.8 | -6.33 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.15 | -0.25 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 113.1x | -78.10 | KOD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.31B | $513.86B | -$507.55B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KOD REV | ABBV REV | KOD GROSS % | ABBV GROSS % | KOD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$136.5M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$117.7M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$154.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KOD // BETA 0.90
ABBV // BETA 1.15